Oral semaglutide reduces non-high-density lipoprotein cholesterol in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.